Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

U.S. stock markets have been enduring severe volatility over the past month. Wall Street’s recent turmoil is broad-based. The ...

The company’s success has been largely built on its HIV treatment portfolio, including the blockbuster drug Biktarvy. Gilead has demonstrated strong operational execution, effectively ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations ...

In the first study, presented by Dr Amy Colson of Community Research Initiative, Boston, people with HIV taking one of the most commonly prescribed regimens, Biktarvy (bictegravir / emtricitabine / ...

Gilead Sciences (GILD) stock fell after The Wall Street Journal reported that the Health and Human Services Department is looking at ...

In the second trial, which was open label, 95.6% of participants who switched to DOR/ISL maintained viral suppression ...

ALLIANCE is an ongoing Phase 3 study to evaluate Biktarvy versus dolutegravir plus emtricitabine/tenofovir disoproxil fumarate F/TDF, DTG+F/TDF, in adults with HIV-1/HBV co-infection initiating ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

So, assuming 2% growth, Gilead is slightly undervalued. In fact, Gilead appears valued for 0% growth. Actually, this may be a ...